GSK PLC-SPON ADR
GSKNYSETrading Snapshot
- Day Range
- $47.70 β $48.73
- 52-Week Range
- $45.83 β $61.70
- Volume (shares)
- 231,709
- Avg Volume (shares)
- β
- Shares Outstanding
- 2.02B
- Next Earnings
- β
Fundamentals Snapshot
- Annual Revenue
- $32.67B
- Last Q Revenue
- $8.82B
- P/E Ratio
- 17.1
- P/S Ratio
- 2.2x
- EPS (TTM)
- $2.17
- Dividend Yield
- 3.74%
- Dilution (1yr)
- β1.4%
GSK PLC-SPON ADR
GSKAbout GSK PLC-SPON ADR
GSK plc, a global pharmaceutical entity founded in 1715 and headquartered in Brentford, United Kingdom, dedicates its efforts to the research, development, and manufacturing of a wide array of medical solutions. Until May 2022, the company was known as GlaxoSmithKline plc. Its primary objective is to prevent and treat illnesses by producing both vaccines and a comprehensive range of specialty and general medicines for markets across the United Kingdom, the United States, and internationally. The company's operations are organized into two key divisions: Commercial Operations and Total R&D. Its extensive vaccine portfolio includes immunizations against shingles, meningitis, respiratory syncytial virus (RSV), seasonal and pandemic influenza, and polio. Beyond preventative care, GSK provides diverse therapeutic products covering critical areas such as HIV, oncology, respiratory and immunology conditions, and other specialized medical fields. This also encompasses inhaled treatments for chronic respiratory ailments like asthma and chronic obstructive pulmonary disease (COPD), along with antibiotics for various infections. Innovation at GSK is frequently driven by strategic partnerships. Notable collaborations include an agreement with CureVac to advance mRNA-based influenza vaccines, and alliances with Wave Life Sciences and Elsie Biotechnologies focused on developing oligonucleotide platforms. Furthermore, GSK has established two distinct strategic collaborations with Relation to progress therapeutics for fibrotic diseases and osteoarthritis. The company is also engaged in a multi-target strategic alliance aimed at developing pioneering treatments for individuals suffering from Parkinson's disease, and a partnership with Flagship Pioneering to identify novel medicines and vaccines.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Latest News & Updates

GSK CFO Points to Cancer Drugs to Bridge Β£3.4 Billion Sales Forecast Gap
GSK (NYSE: GSK) Chief Financial Officer Julie Brown said oncology products could help close the gap between analysts' sales expectations and the company's target of more than Β£40 billion in annual sales by 2031, as it ac

GSK Wins FDA Approval for Nuvalent-Acquired Nelkarmi in Lung Cancer
GSK gains FDA accelerated approval for Nelkarmi in advanced ALK-positive lung cancer, strengthening its oncology portfolio.

GSK Gets FDA Approval for New Lung-Cancer Drug
GSK can now launch a new medicine in the U.S. for lung cancer, a move that bolsters its efforts to build a franchise in a disease that is the leading cause of cancer death.

FDA grants accelerated approval to GSK's lung cancer drug
FDA grants accelerated approval to GSK's lung cancer drug

Aberdeen Group plc Acquires New Stake in GSK PLC Sponsored ADR $GSK
Aberdeen Group plc acquired a new stake in GSK PLC Sponsored ADR (NYSE: GSK) during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional

GSK Targets Β£40 Billion in Sales as HIV Patent Cliff Looms
GSK NYSE: GSK expects to grow through the loss of patent protection for key HIV medicines, relying on a pipeline of new treatments, an expanding oncology business and continued dealmaking, President of Business Developme